Manufacturing Technology

• Patented BDDE purification matrix

• Uniform 3D cross-linking structure

• 0.22μm terminal filtration sterilization

• Lot-controlled aseptic packaging

Clinical Protocol

• Target: Deep dermis / supraperiosteal plane

• Delivery: 25G / 27G cannula recommended

• Technique: Retrograde linear threading

• Dosage constraint: Max 3.0mL per session

Mandatory Medical Disclaimer

Device restricted to administration by licensed medical professionals. Contraindicated for vascular compartments, glabella, and periorbital zones. KFDA Certification #2023-HA-028. Storage strictly at 2-25°C. Avoid freezing. Contains trace HA derivatives (≤0.01%). Volumetric retention varies ±20% based on injection technique and local tissue metabolism.